Axitinib

Last Updated: 04/28/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1899 publications

Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma.

Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma.

Journal: JAMA network open
Published: April 15, 2026

Distribution of Immune Cells in Tumor Microenvironment Correlates With Checkpoint Inhibitor Response in Nasopharyngeal Carcinoma: A Multiregional Study.

Distribution of Immune Cells in Tumor Microenvironment Correlates With Checkpoint Inhibitor Response in Nasopharyngeal Carcinoma: A Multiregional Study.

Journal: JCO global oncology
Published: April 10, 2026

A systematic review on clinical pharmacokinetics and pharmacodynamics of antiangiogenic tyrosine kinase inhibitors (TKIs) with high TDM scores.

A systematic review on clinical pharmacokinetics and pharmacodynamics of antiangiogenic tyrosine kinase inhibitors (TKIs) with high TDM scores.

Journal: Expert review of anticancer therapy
Published: April 08, 2026

Unclear territory: navigating metastatic nonclear cell renal cell carcinoma.

Unclear territory: navigating metastatic nonclear cell renal cell carcinoma.

Journal: Current opinion in oncology
Published: March 24, 2026

Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107).

Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 20, 2026

Clear Cell Renal Cell Carcinoma Recurrence Three Decades After Nephrectomy Presenting With New-Onset Diabetes.

Clear Cell Renal Cell Carcinoma Recurrence Three Decades After Nephrectomy Presenting With New-Onset Diabetes.

Journal: Cureus
Published: February 20, 2026

Mechanistic and translational frontiers on "VEGF and TKI inhibitor axitinib": unfolding drug delivery approaches and opportunities in cancer therapy.

Mechanistic and translational frontiers on "VEGF and TKI inhibitor axitinib": unfolding drug delivery approaches and opportunities in cancer therapy.

Journal: Expert opinion on drug delivery
Published: February 19, 2026

Correction to "Avelumab combined with axitinib for patients with advanced thymoma B3 and thymic carcinoma".

Correction to "Avelumab combined with axitinib for patients with advanced thymoma B3 and thymic carcinoma".

Journal: Cancer
Published: February 10, 2026

Short and Long Non-Coding RNAs in Renal Cell Carcinoma.

Short and Long Non-Coding RNAs in Renal Cell Carcinoma.

Journal: Non-coding RNA
Published: January 24, 2026

Treatment of K562 Cells with ABL Kinase Inhibitors Reveals Differential Metabolic Profiles.

Treatment of K562 Cells with ABL Kinase Inhibitors Reveals Differential Metabolic Profiles.

Journal: Drug research
Published: January 22, 2026

Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma.

Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma.

Journal: Japanese journal of clinical oncology
Published: January 11, 2026

Real-World Effectiveness and Safety of Pembrolizumab-Lenvatinib Versus Axitinib-Based Regimens in Metastatic Clear Cell Renal Cell Carcinoma: A Multicenter Retrospective Study.

Real-World Effectiveness and Safety of Pembrolizumab-Lenvatinib Versus Axitinib-Based Regimens in Metastatic Clear Cell Renal Cell Carcinoma: A Multicenter Retrospective Study.

Journal: International journal of urology : official journal of the Japanese Urological Association
Published: January 06, 2026
Showing 1-12 of 1,899

Last Updated: 04/28/2026